Serration Remodeling Therapy Spotlighted for Complex Peripheral Artery Disease Treatment

According to a recent LinkedIn post from Cagent Vascular Inc, discussion at the VIVA25 conference focused on the use of a 4 mm balloon below the ankle and the role of Serration Remodeling Therapy (SRT) in treating complex peripheral artery disease lesions. The post quotes Dr. Michael Siah outlining a treatment algorithm that positions SRT as a way to address perceived shortcomings of conventional percutaneous transluminal angioplasty (PTA).

The post suggests that SRT is designed to optimize luminal gain, reduce vessel recoil, and minimize dissections across a wide range of lesion morphologies, emphasizing the need for durable outcomes in complex cases. For investors, this emphasis on below-the-ankle and complex-lesion applications may indicate a push to differentiate Cagent Vascular’s Serranator platform in a niche but clinically challenging segment of the PAD market.

If the therapy gains broader clinician adoption as implied by the question, “Is Serration Remodeling Therapy part of your algorithm?”, the company could strengthen its competitive positioning against conventional PTA and other endovascular devices. Expanded use in complex lesions could support higher procedure volumes and premium pricing potential, although commercial impact will depend on reimbursement, clinical data, and real-world uptake beyond conference settings.